Fundraising Fox
Jaguar Health
NASDAQ: JAGXSan Francisco, US · Founded 2013 · Delaware corporation · 2 known investors
Find your way into Jaguar Health
Each arrow is one introduction. Sign up to fill in the first one.
192 people can intro you to Jonathan
Ask Yao Li Ho to introduce you to Jonathan Wolin
You →Yao · together at Berkeley HeartLab, Inc. →Jonathan
Sign up to find every way you can get introduced to Jaguar Health
- Your email: who you already know at Jaguar Health, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Jaguar Health team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Jaguar Health is a pharmaceutical company developing crofelemer, including a novel powder for oral solution formulation, for gastrointestinal conditions and rare intestinal failure indications such as microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) in adults and children. It works through its family companies Napo Pharmaceuticals and Napo Therapeutics.
Founders & leadership
Jaguar Health was founded in 2013 by Lisa Conte.
LC
Lisa ConteFounder
CL
Carol LizakExecutive
PC
Pravin ChaturvediExecutive
JW
Jonathan WolinChief of Staff, Chief Compliance Officer and General CounselHe holds a JD, MBA, and CPA, and brings expertise in regulatory compliance, healthcare reimbursement, and mergers and acquisitions in biotechnology and pharmaceutical industries.
SM
Serge MartinodExecutive
CT
Charles ThompsonExecutive
Board
JB
James BochnowskiBoard director
JM
John Micek, IIIBoard director
AJ
JS
Jonathan SiegelBoard director
GD
Greg DivisBoard director
Investors · 2
BVCFreportedShanghai · $5M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$194.1M disclosed across 42 rounds · 2013–2026
▶$2MraisedJul 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJul 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ConteExecutive Officer, Director
- Carol LizakExecutive Officer
- Steven KingExecutive Officer
- Jonathan WolinExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Jonathan SiegelDirector
- Pravin ChaturvediExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.8MraisedJul 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$40.8MraisedJul 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ConteExecutive Officer, Director
- Carol LizakExecutive Officer
- Steven KingExecutive Officer
- Jonathan WolinExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Jonathan SiegelDirector
- Pravin ChaturvediExecutive Officer
- Offering amount
- $40.8M
- Amount sold
- $40.8M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.8MraisedNov 2025 · PharmaceuticalsRule 506(b)
▶$10.8MraisedNov 2025 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol LizakExecutive Officer
- John Micek IIIDirector
- Jonathan WolinExecutive Officer
- Lisa ConteExecutive Officer, Director
- Anula JayasuriyaDirector
- Pravin ChaturvediExecutive Officer
- Jonathan SiegelDirector
- James BochnowskiDirector
- Steven KingExecutive Officer
- Offering amount
- $10.8M
- Amount sold
- $10.8M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedOct 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedOct 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SiegelDirector
- Steven KingExecutive Officer
- James BochnowskiDirector
- Carol LizakExecutive Officer
- John Micek IIIDirector
- Lisa ConteExecutive Officer, Director
- Jonathan WolinExecutive Officer
- Pravin ChaturvediExecutive Officer
- Anula JayasuriyaDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedSep 2025 · 15 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedSep 2025 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ConteExecutive Officer, Director
- Steven KingExecutive Officer
- Anula JayasuriyaDirector
- Pravin ChaturvediExecutive Officer
- Jonathan WolinExecutive Officer
- Carol LizakExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Jonathan SiegelDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMay 2025 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMay 2025 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol LizakExecutive Officer
- Pravin ChaturvediExecutive Officer
- James BochnowskiDirector
- Lisa ConteExecutive Officer, Director
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Steven KingExecutive Officer
- Jonathan SiegelDirector
- Jonathan WolinExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $190.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60KraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$60KraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol LizakExecutive Officer
- Lisa ConteExecutive Officer, Director, Promoter
- Jonathan B. SiegelDirector
- Jonathan WolinExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Steven KingExecutive Officer
- Offering amount
- $60K
- Amount sold
- $60K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedMay 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedMay 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anula JayasuriyaDirector
- Jonathan B. SiegelDirector
- John Micek IIIDirector
- Steven KingExecutive Officer
- James BochnowskiDirector
- Carol LizakExecutive Officer
- Lisa ConteExecutive Officer, Director, Promoter
- Jonathan WolinExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$7.9Mvaluation at IPOJul 2019 · $2.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updatesfinance.yahoo.com · Aug 2026
Jaguar Health registers 41M shares for resale | JAGX IPO Registration (S-1)stocktitan.net · Jul 2026
Jaguar Health secures $40M equity line, $2M prefs | JAGX 8-K Filingstocktitan.net · Jun 2026Frequently asked questions
- What does Jaguar Health do?
- Jaguar Health is a pharmaceutical company developing crofelemer, including a novel powder for oral solution formulation, for gastrointestinal conditions and rare intestinal failure indications such as microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) in adults and children. It works through its family companies Napo Pharmaceuticals and Napo Therapeutics.
- Who founded Jaguar Health?
- Jaguar Health was founded by Lisa Conte in 2013.
- Who are Jaguar Health's investors?
- Jaguar Health's investors include BVCF, DigitalDx Ventures.
- How much funding has Jaguar Health raised?
- Jaguar Health has disclosed $194.1M raised across 42 rounds.
- Where is Jaguar Health headquartered?
- Jaguar Health is headquartered in San Francisco, US.